We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02981342




Registration number
NCT02981342
Ethics application status
Date submitted
1/12/2016
Date registered
5/12/2016
Date last updated
20/11/2019

Titles & IDs
Public title
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
Scientific title
An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma
Secondary ID [1] 0 0
I3Y-MC-JPCJ
Secondary ID [2] 0 0
16342
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pancreatic Ductal Adenocarcinoma 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Abemaciclib
Treatment: Drugs - LY3023414
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Capecitabine

Experimental: Abemaciclib - Abemaciclib given orally.

Experimental: Abemaciclib + LY3023414 - Abemaciclib given orally and LY3023414 given orally.

Experimental: Standard of Care (Gemcitabine or Capecitabine) - Gemcitabine given intravenously (IV) OR capecitabine given orally.


Treatment: Drugs: Abemaciclib
Administered orally

Treatment: Drugs: LY3023414
Administered orally

Treatment: Drugs: Gemcitabine
Administered IV

Treatment: Drugs: Capecitabine
Administered orally

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Stage 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) - Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Timepoint [1] 0 0
Baseline to Measured Progressive Disease or Start of New Anticancer Therapy (Up to 6 Months)
Primary outcome [2] 0 0
Stage 2: Progression Free Survival (PFS) - PFS was defined as the time from the date of randomization until first observation of objective progressive disease as defined by RECIST v1.1 or death from any cause, whichever comes first. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a patient does not have a complete baseline disease assessment, then the PFS time will be censored at the randomization date, regardless of whether or not objectively determined disease progression or death has been observed for the patient; otherwise, if a patient is not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time will be censored at the last complete objective progression-free disease assessment date.
Timepoint [2] 0 0
Baseline to Measured Progressive Disease or Death Due to Any Cause (Up to 6 Months)
Secondary outcome [1] 0 0
Stage 1: Objective Response Rate (ORR): Percentage of Participants With a Best Overall Response (BOR) of CR or PR - Objective response rate (ORR) is the percentage of participants with a BOR of CR or PR as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
Timepoint [1] 0 0
Baseline to Measured Progressive Disease or Start of New Anti-Cancer Therapy (Up to 6 Months)
Secondary outcome [2] 0 0
Stage 1: Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib and Its Metabolites (LSN2839567 (M2), LSN3106726 (M20)) - Mean steady state exposure was reported as measured by maximum observed plasma concentration (Cmax).
Timepoint [2] 0 0
Cycle(C)1 Day(D)14: 0 hour(h),0.5h,1h,2h,4h,6h,8h post dose
Secondary outcome [3] 0 0
Stage 1: PK: Area Under the Curve (AUC) (AUC[Tau]) of LY3023414
Timepoint [3] 0 0
Cycle 1 Day 1 through Cycle 4 Day 1 (28 Day Cycles)
Secondary outcome [4] 0 0
Stage 1: PK: Maximum Concentration (Cmax) at Steady State of LY3023414
Timepoint [4] 0 0
Cycle 1 Day 1 through Cycle 4 Day 1 (28 Day Cycles)
Secondary outcome [5] 0 0
Stage 2: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and SD
Timepoint [5] 0 0
Baseline to Measured Progressive Disease or Start of New Anticancer Therapy (Up to 6 Months)
Secondary outcome [6] 0 0
Stage 2: Clinical Benefit Rate (CBR): Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months - Clinical benefit rate (CBR) is the percentage of participants with a BOR of CR or PR, or SD =6 months. CR is defined as the disappearance of all target and non-target lesions & no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
Timepoint [6] 0 0
Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 6 Months)
Secondary outcome [7] 0 0
Stage 2: Duration of Response (DoR)
Timepoint [7] 0 0
Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Up to 6 Months)
Secondary outcome [8] 0 0
Stage 2: Overall Survival (OS) - OS duration is measured from the date of randomization to the date of death from any cause. for participants who is not known to have died as of the data-inclusion cutoff date, OS was censored at the last known alive date.
No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
Timepoint [8] 0 0
Baseline to Death from Any Cause (Up to 10 Months)
Secondary outcome [9] 0 0
Stage 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA 19-9) Level - No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
Timepoint [9] 0 0
Baseline, 6 Months
Secondary outcome [10] 0 0
Stage 2: Change From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf) - mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity. In addition to pain intensity (4 items), the mBPI-sf is designed for participants to record the presence of pain in general, pain relief, and pain interference with function (general activity, mood, ability to walk, ability to perform normal work, relations with others, sleep, and enjoyment of life). Responses for the mBPI-sf items are captured through the use of 11-point numeric rating scales anchored at 0 (no pain or does not interfere) and ranged through 10 (pain as bad as you can imagine or completely interferes). The mBPI-sf recall period is 24 hours, and typical completion time for this instrument is less than 5 minutes.
No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
Timepoint [10] 0 0
Baseline, 6 Months
Secondary outcome [11] 0 0
Stage 2: Change From Baseline in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) - The EORTC QLQ-C30 self-reported general cancer instrument consists of 30 items covered by 1 of 3 dimensions:
Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent).
Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much)
Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much).
Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden.
No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
Timepoint [11] 0 0
Baseline, 6 Months
Secondary outcome [12] 0 0
Stage 1: PK: Steady State Trough Pre Dose Concentration of LY3023414 - Mean steady state exposure was reported by trough pre-dose plasma concentrations.
Timepoint [12] 0 0
C2D1: 0h, C3D1: 0h, C4D1: 0h
Secondary outcome [13] 0 0
Stage 1: PK: Mean Single Dose Concentration of LY3023414 at 2h Post-dose - Mean single dose exposure was reported by plasma concentrations collected approximately 2 hours post-dose.
Timepoint [13] 0 0
C1D1: 2h Post dose

Eligibility
Key inclusion criteria
- Histological or cytological diagnosis of ductal adenocarcinoma of the pancreas.

- Metastatic disease with documented disease progression following previous treatment
with at least one, but no more than 2 prior therapies, with one of the prior therapies
having been either gemcitabine-based or fluoropyrimidine-based therapy. Neoadjuvant
and/or adjuvant therapies for localized resectable or unresectable PDAC each count as
a line of therapy if multiagent chemotherapy regimens were administered (and
neoadjuvant regimen was different than adjuvant regimen) and if the participant
progressed with metastatic disease while taking or within 6 months of completion of
(neo)adjuvant therapy.

- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

- Participant for whom treatment with monotherapy chemotherapy such as gemcitabine or
capecitabine is a reasonable choice.

- Discontinued all prior treatment for cancer at least 14 days prior to initial dose of
study treatment.

- Adequate organ function.

- allow alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 5x
upper limit of normal (ULN) if liver metastases.

- allow bilirubin up to 2.5 times ULN if elevation is not associated with other
signs of liver toxicity or can be explained by mechanical obstruction - requires
clinical research physician approval.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Have a personal history of any of the following conditions: syncope of either
unexplained or cardiovascular etiology, ventricular arrhythmia (including but not
limited to ventricular tachycardia and ventricular fibrillation), or sudden cardiac
arrest. Exception: Participants with controlled atrial fibrillation for >30 days prior
to study treatment initiation are eligible.

- Have insulin-dependent diabetes mellitus. Participants with type 2 diabetes mellitus
are eligible if adequate control of blood glucose level is obtained by oral
anti-diabetics as documented by hemoglobin A1c (HbA1c) <7%.

- Have symptomatic central nervous system metastasis. Screening of asymptomatic
participants is not required for enrollment.

- Have had major surgery within 7 days prior to initiation of study drug to allow for
postoperative healing of the surgical wound and site(s).

- Have previously received treatment with any cyclin-dependent kinase (CDK) 4 and 6
inhibitor or phosphatidylinositol 3-kinase (PI3K) and/or mammalian target of rapamycin
(mTOR) inhibitor or have a known hypersensitivity to any component of the
investigational products in this study.

- Have a known hypersensitivity to investigator's choice of standard of care
(gemcitabine or capecitabine).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician. - Blacktown
Recruitment hospital [2] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Sydney
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
2010 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Connecticut
Country [2] 0 0
United States of America
State/province [2] 0 0
Illinois
Country [3] 0 0
United States of America
State/province [3] 0 0
Missouri
Country [4] 0 0
United States of America
State/province [4] 0 0
New Hampshire
Country [5] 0 0
United States of America
State/province [5] 0 0
Pennsylvania
Country [6] 0 0
United States of America
State/province [6] 0 0
Tennessee
Country [7] 0 0
United States of America
State/province [7] 0 0
Washington
Country [8] 0 0
United States of America
State/province [8] 0 0
Wisconsin
Country [9] 0 0
Belgium
State/province [9] 0 0
Brussels
Country [10] 0 0
Belgium
State/province [10] 0 0
Edegem
Country [11] 0 0
Belgium
State/province [11] 0 0
Leuven
Country [12] 0 0
Belgium
State/province [12] 0 0
Wilrijk
Country [13] 0 0
France
State/province [13] 0 0
Lyon
Country [14] 0 0
France
State/province [14] 0 0
Paris
Country [15] 0 0
France
State/province [15] 0 0
Pessac
Country [16] 0 0
Israel
State/province [16] 0 0
Haifa
Country [17] 0 0
Israel
State/province [17] 0 0
Ramat Gan
Country [18] 0 0
Israel
State/province [18] 0 0
Tel Aviv
Country [19] 0 0
Spain
State/province [19] 0 0
Barcelona
Country [20] 0 0
Spain
State/province [20] 0 0
Hospitalet de Llobregat
Country [21] 0 0
Spain
State/province [21] 0 0
Madrid
Country [22] 0 0
Spain
State/province [22] 0 0
Malaga
Country [23] 0 0
Taiwan
State/province [23] 0 0
Tainan
Country [24] 0 0
Taiwan
State/province [24] 0 0
Taipei city
Country [25] 0 0
Taiwan
State/province [25] 0 0
Taipei
Country [26] 0 0
United Kingdom
State/province [26] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in
combination with other drugs versus standard of care in participants with previously treated
metastatic pancreatic ductal adenocarcinoma (PDAC).
Trial website
https://clinicaltrials.gov/show/NCT02981342
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications